about
Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.Concomitant BET and MAPK blockade for effective treatment of ovarian cancer.BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinomaAdaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma.Downregulation of bone morphogenetic protein receptor 2 promotes the development of neuroblastoma.Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit.SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma.Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer.Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex.Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics
P50
Q27307642-3A3ED3D2-A245-45AC-B7D7-D7E5E16F9FD9Q35843618-A87DE65F-7465-439A-B2A9-C406DD09447DQ36510858-557C6A53-87A9-4BB2-AD6B-045A33E7061BQ36771909-12CC4C5F-E2BC-43FE-9C49-2A9290339B30Q36970403-5B9E2118-F39C-42E0-A14C-938F641C2350Q37157371-904C21BF-2BA7-4E45-AC7B-9C151CD3E899Q37561673-984E9133-35F3-4BCF-9E38-8405C4B85276Q38725194-B9E27936-8A26-444C-8555-3018F2B87299Q38864482-1E403B13-1163-4061-81AF-B4A9243C47FAQ39037593-8C6C6149-21D2-491C-B49A-431794E9BC5FQ47293181-48C011A1-42A7-49E8-BE71-29249D81E1EEQ48240262-A187B10C-C168-4806-BA25-1E23F6A7E235Q48785713-012E9B54-1CD5-45AA-9676-697A1CD46774Q52661725-7D2B34A7-1B27-4A4C-B303-5670BC7AAF3DQ54346071-5BE6A0D0-433D-4305-95F6-267BA98AF61CQ88044882-5AAE69AB-A552-4472-B2DF-B88C5E3AFAD0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ying Jing
@ast
Ying Jing
@en
Ying Jing
@es
Ying Jing
@nl
Ying Jing
@sl
type
label
Ying Jing
@ast
Ying Jing
@en
Ying Jing
@es
Ying Jing
@nl
Ying Jing
@sl
prefLabel
Ying Jing
@ast
Ying Jing
@en
Ying Jing
@es
Ying Jing
@nl
Ying Jing
@sl
P106
P1153
55942814200
P31
P496
0000-0001-6364-6130